Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | INMUNOSUN-SOGUG trial: sunitinib second line metastatic RCC

Enrique Grande, MD, of the MD Anderson Cancer Center Madrid, Madrid, Spain, highlights data coming from the INMUNOSUN-SOGUG trial (NCT03066427), a prospective phase II study investigating the efficacy of second line sunitinib, a tyrosine kinase inhibitor, in patients who have failed first line, immunotherapy treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.